Pomerantz Law Firm Investigates Securities Fraud Claims Against Aardvark Therapeutics, Inc.

Introduction

In a significant development for shareholders, Pomerantz Law Firm has initiated an investigation into Aardvark Therapeutics, Inc. (NASDAQ: AARD) to determine the validity of claims regarding securities fraud and unlawful business practices. Investors who believe they have been affected are encouraged to come forward and provide their accounts. The focus of the investigation centers on troubling announcements made by Aardvark that have affected its stock performance and investor confidence.

Background of Aardvark Therapeutics

Aardvark Therapeutics is a biopharmaceutical company focused on developing therapies that address unmet medical needs. Recently, the company has been in the spotlight due to a critical update concerning its clinical trials, particularly the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial. On February 27, 2026, Aardvark publicly declared that it would halt the HERO trial due to "reversible cardiac observations at above target therapeutic doses". This shocking revelation has left many investors uneasy about the potential implications.

Stock Price Impact

Following the announcement regarding the suspension of the HERO trial, Aardvark's stock plummeted by $7.02, marking a steep decline of 56.2% and closing at $5.47 per share on March 2, 2026. Such a drastic fall in stock price has left investors questioning the company’s operational integrity and the transparency of its communications. This situation has prompted Pomerantz LLP to explicitly investigate whether Aardvark's executives misled investors regarding the safety of their clinical trial results.

Further Developments

In a subsequent press release dated May 14, 2026, Aardvark announced that the U.S. Food and Drug Administration (FDA) had imposed a full clinical hold on its investigational new drug application (IND) for ARD-101 due to concerns stemming from the halted HERO trial. The FDA's clinical hold affects all ongoing studies under the IND, including significant trials aimed at treating hyperphagia in patients with Prader-Willi Syndrome. The immediate result was another significant drop in stock value, shedding $2.16 per share or 32.1%, closing at $4.57 on May 15, 2026.

Legal Implications

The role of Pomerantz LLP in this scenario cannot be understated. Renowned for its work in corporate, securities, and antitrust class litigation, the firm is now investigating claims that Aardvark and its directors potentially violated securities laws. Investors who suffered losses during this turbulent period are encouraged to reach out to Pomerantz for potential inclusion in a class-action lawsuit aimed at mitigating their losses and holding the company accountable.

Conclusion

As developments unfold, the focus will remain on Aardvark Therapeutics and its response to these issues. The ability of the company to restore investor confidence hinges not only on its future announcements but also on how transparently and effectively it addresses the current allegations. Interested investors or those affected by these events are advised to connect with Pomerantz LLP for more information. The firm's long history of pursuing justice for victims of corporate misconduct provides some hope for those seeking remedies in this troubling situation.

For further information about joining the potential class action or for inquiries, investors can contact Danielle Peyton at Pomerantz LLP via email at [email protected] or by phone at 646-581-9980, ext. 7980.